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Introduction: We sought to evaluate quality of life patients with myasthenic crisis before and
after therapeutic plasma exchange.
Materials and methods: In our study we conducted an assessment of the quality of life with
the use of the questionnaire SF-36, when executed eleven therapeutic plasma exchange. The
assessment was made on baseline and after 4 weeks. We also did neurological clinical
evaluation before and after TPE.
Results: Patients in the study showed signiﬁcant improvement in quality of life after
performed therapeutic plasma exchange. The changes were observed in physical function-
ing, which conﬁrmed the results of the statistical signiﬁcance of p < 0.05. In the analysis, the
assessment of mental functioning not obtained the results of statistical signiﬁcance, but the
results also showed improvement in self-assessment. We observed high correlation be-
tween general health and physical mental functioning, between the role limitations due to
physical health problems and role limitations due to emotional problems, and general
health perception and bodily pain.
Conclusions: Therapeutic plasma exchange signiﬁcantly improves the quality of life of
patients with myasthenia gravis during the crisis.
# 2016 Polish Neurological Society. Published by Elsevier Sp. z o.o. All rights reserved.
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Myasthenia gravis (MG) is an acquired autoimmune disease
with pathomechanism based on production of antibodies
directed against acetylocholine receptors (anti-AchR) of the
postsynaptic membrane of the neuromuscular junction. The* Corresponding author at: Department of Neurology, Medical Univers
Tel.: +48 32 3704584; fax: +48 32 3704597.
E-mail address: irozmilowska@gmail.com (I. Rozmilowska).
http://dx.doi.org/10.1016/j.pjnns.2016.07.005
0028-3843/# 2016 Polish Neurological Society. Published by Elsevier Sepidemiological examinations showed that the disease occurs
with frequency of 10–15 persons per 100,000 population. The
main symptom of myasthenia is progressive muscle fatigabil-
ity, the typical of which are: apokamnosis symptoms of limbs
muscles and mimetic muscles, diplopy, eyelids drooping,
‘‘snarling’’ smile the so-called Gioconda's syndrome, difﬁculty
chewing, dysphagia, dysarthria [1]. In conformity withity of Silesia, ul. 3-go Maja 13-15, 41-800 Zabrze, Poland.
p. z o.o. All rights reserved.
Table 1 – Demographic and clinical characteristics of
patients enrolled into the study.
TPE (n) 11
Average age (years) 59 (51–71)
Gender (%) 75 (female)
25 (male)
The mean duration of
illness (years)
14 (3–32)
Tymectomia (%) 80 (%)
Main neurological
symptoms before TPE (%)
Apokamnosis symptoms
of limbs muscles and
mimetic muscles (100%)
Diplopy (81%)
Eyelids drooping (75%)
Difﬁculty chewing (63%)
Dysphagia (75%)
Dysarthria (81%)
Dyspnoea (81%)
Electrical activity in repetitive
nerve stimulation (%)
Positive (100%)
Antibodies against AchR before TPE
(nmol/l) [range/mean]
15.8–1300 (253.17)
Antibodies against AchR after TPE
(nmol/l) [range/mean]
39.4–320 nmo/l/179.7
Treatment (%) Anticholinesterase
drugs (100%)
Prednisone (27%)
Azathioprine (18%)
CRP (mg/l) [range/mean] 0.48–20.92/4.24
TPE – therapeutic plasma exchange, CRP – C-reactive protein.
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distinguished: ocular (type 1) and generalized (type 2). The
criteria for classiﬁcation of patients into particular types of
myasthenia are exclusively clinical symptoms [2,3].
The diagnostics of myasthenia is based on marking the
level of antibodies anti-AChR, which occur at 85% patients.
The remaining 15% described as seronegative may have other
types of antibodies, such as against muscle-speciﬁc tyrosine
kinase (anty-MuSK) or antititin antibodies [4–6]
In case of rapid increase of the symptoms and acute course
of the disease leading to respiratory inefﬁciency talk about the
myasthenic crisis. It is estimated that every ﬁfth patient has at
least one myasthenic crisis in a lifetime and, if the disease is
accompanied by thymoma, the risk increases to 50% [7]. The
myasthenic crisis usually occurs at patients with generalized
type of disease, the symptoms of respiratory inefﬁciency are
accompanied by signiﬁcant fatiguing of muscles, swallowing
disorders, bulbar palsy [8].
The standard procedure in case of the occurrence of the
myasthenic crisis is treatment of the patient in an intensive
care ward. It is important to implement the therapy
(plasmapheresis or intravenous supply of immunoglobulins)
as soon as possible, which will allow the shortening of
application of mechanical ventilation and limitation of the risk
of complications [9].
The patients with diagnosed myasthenia are characterized
by a signiﬁcant variability of the course of their disease. Some
of them complain on numerous clinical symptoms, which in a
small or a bigger extent make everyday life difﬁcult. The
patients understand the concept of health as a functional
condition and a quality of life with the disease. The evaluation
of the quality of life has in recent years become an important
element of everyday medical practice, since the purposes of
modern medicine are both prolonging patients' lives as well as
improvement and approximating the quality of life to the
condition before the disease. In our research we mainly use the
deﬁnition of the quality of life condition by the health
condition (health related quality of life – HRQOL). This value
is estimated subjectively by a patient and involves the
comparison of the present health condition with the expected
condition using respectively general questionnaires, speciﬁc
and mixed questionnaires [10].
The aim of our study was to evaluate for the ﬁrst time in our
Polish population patients with myasthenic crisis the quality
of life before and after therapeutic plasma exchange.
2. Materials and methods
2.1. Patient population
Into the prospective study eleven cases diagnosed with
myasthenia during the myasthenic crisis who had been
qualiﬁed for TPE were enrolled. Only conscious, cooperating,
able to fulﬁlling the questionnaires subjects were included into
the study. Demographic patients' characteristics were pre-
sented in Table 1. TPE were conducted in patients submitted to
therapeutic plasma exchange during years 2012–2015 in the
Ward of Anaesthesiology and Intensive Therapy. The work
described in this article has been carried out in accordancewith the Code of Ethics of the World Medical Association
(Declaration of Helsinki) for experiments involving humans Nr
KNW/0022/KB1/68/15; uniform requirements for manuscripts
submitted to biomedical journals.
2.2. Therapeutic plasma exchange
TPE (plasmapheresis) is a method of blood puriﬁcation
allowing to remove inﬂammatory mediators and antibodies
by using extracorporeal circuit. The procedure is used in a
variety of conditions, including autoimmune diseases like
myasthenia (indication IA during American Society for
Apheresis) [11]. TPE is an invasive procedure, but when
performed by properly trained and qualiﬁed staff, it is
relatively safe [12–14]. Life-threatening episodes like shock
(anaphylactic or septic), hypotension requiring vasopressor
drugs or bleeding are rare [12–14]. The most frequent, but not
very severe complications are urticaria, pruritus, hypocalcae-
mia and mild hypovolemia. Adverse effects are associated
more commonly with the administration of fresh-frozen
plasma (FFP) used as a replacement solution compared to
human albumin solutions.
Patients with diagnosed myasthenia were qualiﬁed to TPE
by neurologist, based on clinical state and the level of
acetylcholine receptor binding antibodies. In Poland TPE is
performed in Intensive Care Units, regarding patient's clinical
state, often requiring respiratory or circulatory support.
Because of many different indications (plasmaphereses are
used in treatment of about 150 diseases) and various
equipment available, one standard TPE protocol does not
exist. We developed our own TPE protocol based on previous
Table 2 – MGFA clinical classification.
Class I Any ocular muscle weakness; may have weakness of eye closure. All other muscle strength is normal.
Class II a Mild weakness affecting muscles other than ocular muscles; may also have ocular muscle weakness of any severity.
Predominantly affecting limb, axial muscles, or both.
Class II b Mild weakness affecting muscles other than ocular muscles; may also have ocular muscle weakness of any severity.
Predominantly affecting oropharyngeal, respiratory muscles, or both.
Class III a Moderate weakness affecting muscles other than ocular muscles; may also have ocular muscle weakness of any severity.
Predominantly affecting limb, axial muscles, or both.
Class III b Moderate weakness affecting muscles other than ocular muscles; may also have ocular muscle weakness of any severity.
Predominantly affecting oropharyngeal, respiratory muscles, or both.
Class IV a Severe weakness affecting muscles other than ocular muscles; may also have ocular muscle weakness of any severity.
Predominantly affecting limb, axial muscles, or both.
Class IV b Severe weakness affecting muscles other than ocular muscles; may also have ocular muscle weakness of any severity.
Predominantly affecting oropharyngeal, respiratory muscles, or both.
Class V Deﬁned as intubation, with or without mechanical ventilation, except when employed during routine postoperative
management. The use of a feeding tube without intubation places the patient in class IVb.
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ﬁltration types of plasmapheresis is performed with standard
heparine anticoagulation, using TPE 2000 ﬁlter for Prismaﬂex
eXeed system (Gambro-Baxter). The central venous catheter 12
Fr is inserted with ultrasound guidance using Seldiger
technique, usually via right internal jugular vein. Standard
biochemistry, morphology, coagulation, electrolytes and blood
arterial gases are assessed in every patient. Before starting the
procedure, patients are given 500–1000 ml of crystalloid ﬂuid
with calcium. During one session the exchanged plasma
volume is 50 ml h1with median 3000 ml. It is about 1–1.2 of
estimated plasma volume (EPV) according to Kaplan rule:
EPV = [0.065  weight (kg)  (1  Ht)]. Blood ﬂow rate was set at
2 times body weight, but did not exceed 200 ml h1. As a
replacement ﬂuid we used PrismaSol 4 or Phoxilium (contain-
ing 1.2 mmol phosphate) dialysate solution with mean ﬂow
rate of 700 ml h1. Additionally, every patient received 450–
500 ml of 20% human albumin solution (Flexbumin, Baxter)
immediately via peripheral vein access. Anticoagulation is
maintained with heparin infusion 800–1000 IU h1, without
additional boluses. Fluid removal from the patient depends on
haemodynamic stability. Median duration of session was 5 h.
At the end of each session, one unit of FFP was administered,
as well as vitamins and calcium. Sessions were repeated every
day or every other day. After 3–4 sessions signiﬁcant clinical
improvement was observed. In our group no treatment was
discontinued due to a complication or clotting in circuit. In 2
cases mild hypotonia was observed, in 2 cases transient
dysrhythmias occurred due to electrolyte imbalance. No
serious adverse events were observed [12–15].
2.3. Neurological clinical evaluation
We used standard classiﬁcation system for the neurological
clinical evaluation before and after TPE. Myasthenia Gravis
Foundation of America clinical classiﬁcation (MGFA) may be
used to deﬁne prognosis and possible response to treatment.
Class I is mild in nature, Classes II, III and IV may be further
subdivided into category 'a', which primarily impacts the
limbs, or 'b', which primarily affects the respiratory muscles or
those of the tongue or mouth. Class V is the most severe form
requiring intubation [16]. Table 2 showed complete MGFA
Clinical Classiﬁcation.2.4. Quality of life evaluation
Before and after TPE procedure the patients were asked to ﬁll a
validated Polish language version SF-36 form created by
Professor J. Tylka on the basis of original English language
version The Short Form 36 Health Survey [17,18]. It consists of
thirty six questions assessing: PF – physical functioning, RLP –
role limitations due to physical health problems, BP – bodily
pain, SF – social functioning, GMH – general mental health,
RLE – role limitations due to emotional problems, VT – vitality,
GHP – general health perception. An additional parameter
assessed in the form is a change in the health condition over
time (a recent year). This index was not included in the above
components of SF-36. Categories are grouped in two scales:
physical (PCS – Physical Component Scores) and mental (MCS
– Mental Component Summary). To scale PCS included in
categories: PF, RPL, BP, GHP, and to the scale of MCS –
Categories: RLE, SF, GMH, VT.
The answers to each question are evaluated according
to a point scale and then converted into particular
numeric values for speciﬁc indices. The results are pre-
sented separately for each of the eight indices and in total
for all components of form SF-36 as HRQOL – health quality
of life index. The maximum scores to evaluate the quality of
life in questionnaire SF 36 is 171 points, where the physical
aspect of life is maximum 103 points, and psychical 68
points.
The overall assessment serves to determine the quality of
life where in conformity with the Polish interpretation it was
assumed that the highest point value means the lowest degree
in evaluation of the quality of life and the lowest value – the
highest quality of life level.
2.5. Statistical analysis
The study results were conducted on the grounds of statistical
analysis for quantitative parameters, for which basic descrip-
tive statistics were determined: average, standard deviation,
median, extreme values, variations. The force and direction of
interdependence of the score in SF-36 form before and after the
TPE was determined using Spearman' correlation coefﬁcient r.
The statistical analysis was conducted using programmes
STATISTICA v. 12 PL and EXCEL.
Table 3 – The summary of MGFA Clinical Classification in
patients before and after TPE.
Patient no. MGFA Class
before TPE
MGFA Class
after TPE
1 III a II a
2 IV b II a
3 IV a I
4 III a I
5 IV b I
6 IV a II a
7 IV b II b
8 III b II b
9 III a II a
10 V II b
11 IV b II a
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Results from our study obtained from the SF-36 form indicate
that the patients after TPE notice improvement the quality of
life in all examined components in the group of patients
qualiﬁed for the therapeutic plasma exchange during the
course of aggraviation of a myashtenia. The overall coefﬁcient
of the SF-36 amounted on average 119.81 and 83.90 points
( p < 0.05) before and after the treatment, respectively.
Neurological clinical evaluation also showed positive
changes in all patinets. MG patients before TPE were
categorized in range IIIa–V according to the MGFA Clinical
Classiﬁcation. MG cases after TPE were categorized in range
I–IIb according to the MGFA. Table 3 presents a summary of
MGFA Clinical Classiﬁcation in patients before and after TPE.
Physical Component Scores – PCS, which consists of
physical functioning (PF), role limitations due to physical
health problems (RLP), bodily pain (BP) and general health
perception (GHP) showed a statistically signiﬁcant correlation
(p < 0.05) as regards the self-assessment of the quality of life
before and after the therapeutic plasma exchange.
The compared results of Mental Component Scores – MCS,
consisting of: social functioning (SF), role limitations due to
emotional problems (RLE), general mental health (GMH) and
vitality (VT) do not signiﬁcantly differ as regards the self-
assessment of the quality of life in this area (p > 0.05). The
health condition changes over time not included in the
assessment of physical and mental health did not show
signiﬁcant differences (p > 0.05) among the examined
patients. Table 4 presents a summary of SF-36 form results
in particular categories for the examined patients.
The subjective improvement quality of life is conﬁrmed by
results from clinical examination. The patients with slight
disease severity (MGFA class IIIa and IIIb) had a lower PCS, that
mean higer quality of physical functioning after TPE. MG
patients of the MGFA Class IVa, IVb and V achieved a higher
rate of PCS. Results show signiﬁcant differences (p < 0.05). The
MGFA Class changes compared in the assessment of mental
health did not show signiﬁcant differences (p > 0.05) among
the examined patients.Table 4 – The SF-36 – summary of results of patients before an
B
Mean 
Physical functioning (PF)a 39 
Role limitations due to physical healths problems (RLP)a 19.09 
Bodily pain (BP)a 4.45 
General health perception (GHP)a 14.72 
Social functioning (SF)a 5.09 
General mental health (GMH)a 9.64 
Role limitations due to emotional problems (RLE)a 10.45 
Vitality (VT)a 14.09 
Health Changea 3.27 
TPE – therapeutic plasma exchange.
a Points.Differences in quality of life in particular domains are not
homogenous. The patients notice the biggest improvement
mainly in physical condition aspect. In the scope of physical
limitations quality of life the patients who had undergone TPE
obtained lower scores in comparison to self-assessment
during the period of aggraviation of myasthenia, i.e. before
the treatments. The patients scored respectively 56.54 vs 77.27
points. The lower score means higher quality of life. The most
signiﬁcant differences were noted in categories: physical
functioning, general health perception and bodily pain. The
differences in these categories were statistically signiﬁcant
(p < 0.05) and amounted respectively – for PF 39.0 vs 28.63, for
GHP 14.72 vs 10.72 and for BP 4.5 vs 3.5 points.
The quality of life assessment in the mental sphere did not
show any statistically signiﬁcant differences. The patients
before TPE scored 39.27 points, and after therapeutic plasma
exchange – 26.45 points. The biggest improvement was noticed
in category role limitations due to emotional problems 10.5 vs
5.5 and vitality 14.1 vs 8.72 poitns (Fig. 1).
Spearman correlation analysis between the dimensions of
health showed a high correlation between general health and
physical mental functioning (r = 0.72), between the role
limitations due to physical health problems and role limita-
tions due to emotional problems (r = 0.62), and general health
perception and bodily pain (r = 0.74).d after TPE.
efore TPE After TPE
Median SD Mean Median SD p
44 13.34 28.63 34 11.21 <0.05
20 2.02 16.63 15 4.52 NS
5 1.69 3.54 4 1.21 <0.05
15 4.84 10.72 11 2.45 <0.05
6 1.76 2.81 3 1.54 NS
8 5.08 9.45 8 6.04 NS
15 6.11 5.45 5 4.16 NS
16 4.78 8.72 9 3.35 NS
4 1.42 0.9 1 0.94 NS
Fig. 1 – Quality of life (SF-36) before TPE, after TPE and
general Polish population – average results obtained in
each category (points) [28].
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Our study proved improvement in the quality of life scores in
patients with myasthenia after therapeutic plasma exchange.
The increased interest in quality of life depends on the health
in the context of existing chronic disease is now one of the
most important trends in research. Quality of life allows to
assess the inﬂuence by illness and treatment on physical,
mental and social development of the patient and can be
helpful in building a comprehensive therapeutic strategy,
relating not only to improve the physical aspect. In patients
with myasthenia, particularly because it is a chronic disease
which affects signiﬁcantly the patients' quality of life
depending on the intensity of neurological symptoms. If a
myasthenic crisis occurs, the patients' functioning rapidly
deteriorates and thus the quality of life level decreases. The
questionnaire SF-36 questionnaire as a general, was chosen for
this study because of its complexity and the high standard of
reliability and credibility. Analysis of results also showed that
the MGFA Clinical Classiﬁcation is corresponding with
subjective quality of life patients with myasthenia. It becomes
a important predictor of clinical results after TPE treatment.
The MGFA class is actually used in evaluation of neurological
changes after different treatment of myasthenia, in patient
with thymoma and after surgical intervention or as prognostic
factor. It gives possibility to objectively clinical evaluation [19].
Our assumptions before study were that the scores in the
group after the treatment would be signiﬁcantly better,
especially in the aspect of physical functioning. We received
statistical results p < 0.05 what conﬁrmed our assumptions.Signiﬁcant improvement after TPE was also noticed in the
mental functioning, but no statistical results were obtained.
In conformity with current guidelines the TPE show
efﬁciency comparable to immunoglobulins 'treatment in the
course of mysthenic crisis [20]. The so-far conducted research
did not prove signiﬁcant advantage of one of these methods,
however, the improvement effect is usually faster achieved
after TPE application. The equivalence of both above men-
tioned treatments provides a free possibility of choosing a
procedure and adjusting a proper scheme of procedures for a
speciﬁc patient [21,22].
So far in the literature there were scarce works concerning
the quality of life patients with myasthenia. Barnett et al. in
their study compared the improvement in the quality of life
(HRQOL) after immunomodulation. They assessed the ques-
tionnaire MG-HRQOL-60 after IVIG and TPE in 62 patients and
then analyzed the change in the HRQOL scores from baseline
to day 14 in both treatment groups. Results showed the scores
in both HRQOL scales decreased at day 14 in the IVIG and TPE
groups, without signiﬁcant difference between groups.
Changes observed in questionnaire MG-HRQOL-60 presents
that IVIG and TPE are comparable in the treatment of patients
with myasthenia [23]. In our study we also observed
improvement in quality of life after TOP. Most signiﬁcantly
changes were shown in physical functioning, especially in
physical functioning, general health perception and bodily
pain. Results were statistically signiﬁcant (p < 0.05).
Study conducted by Chen et al. appraised the effects of
improvement in muscle strength after TPE on both quality of
life and psychological status of MG patients. Psychosocial tests
showed signiﬁcant pre- and posttherapy differences in illness
identity and disability. Patients especially were achieving
immediate improvement of myasthenic symptoms but emo-
tional status and HRQOL did not differ signiﬁcantly after
intervention [24]. Our observations were similarly. Mental
functioning has been less improvement than the physical
aspect, and the results did not reach statistical signiﬁcance.
Boldingh et al. in their work assessed the quality of life
patients in Scandinavian countries diagnosed with myasthe-
nia compared to general population. Used in this study SF-36
form assessed the recent four weeks from patients' lives. The
patients were divided depending on clinical symptoms of the
disease, disease remission period, gender, applied treatment,
antibodies presence and thymoma. No statistically signiﬁcant
differences between HRQOL at patients with diagnosed
myasthenia versus general population were found. Neverthe-
less, it was observed that certain conditionings, such as female
gender, general fatigability or usage of secondary non-steroid
immunosuppressive were risk factors to reduced HRQOL [25].
The research conducted by Padua et al. in Italian population
was involved the evaluation of the correlation of neurological
symptoms and repetitive nerve stimulation patients with
myasthenia. Results were compared to HRQOL outcomes
based on SF-36 form both patients with MG and health
population. All domains were reduced in patients with
myasthenia (lower HRQOL) compared to normative Italian
population [26]. In reference to the above two studies, in our
study we made a summary of the results obtained in patients
with myasthenia before and after TPE with respect to the norm
of Polish population in HRQOL (based on SF-36). The results are
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diagnosed with myasthenia showed lower HRQOL compared
to the general population, without statistically signiﬁcant
differences (p < 0.05).
Kilkantrakorn et al. reported that mental functioning
results showed the lowest scores (lower HRQOL) while other
components were in average or high range. Better physical
functioning were observed in patients with ocular and mild
generalized myasthenia. Immunosuppressive treatment was
not associated with low quality of life. Females had lower
scores of HRQOL in MG patients using SF-36 form [27]. Our
results indicate similar conclusions. Patients with mild
symptoms of myasthenia had a better result in evaluation
of quality of life. Mental functioning showed lower improve-
ment in HRQOL after TPE than physical aspect of life.
Amount of studies conducted so far in assessing the quality
of life of patients with MG treated IVIG or TPE is still low.
However, for patients changes that improve their physical,
psychological and social aspects of life are very important.
Myasthenia is a chronic disease with which patients have to
struggle for life. Systematical evaluation for patients' illness
perceptions and emotional problems are warranted and
related strategies should be taken for long-term stabilization
of psychosocial function.
5. Conclusions
In conformity with the our obtained results the patients
treated with TPE together with disappearance of clinical
symptoms observed a signiﬁcant improvement in their quality
of life. Signiﬁcant differences regarded the physical function-
ing aspect. It may be said that nowadays the patients' quality
of life is also an element of the treatment efﬁciency. A
possibility to have family and professional life, do every day
activities without obstacles is an important indicator in all
assessments. We are aware about the limitation of our study
what is the number of patients qualiﬁed for TPE. Further
studies concerning the assessment of the quality of life among
patients with myasthenia are planning.
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